fbpx Skip to main content

Public Policy Newsletter Article

Biocom California Advocates Against Upcoming Drug Pricing Legislation

  • 2021-04-22T15:00:00.000+0000
  • Author: Laure Fabrega

Biocom California has been advocating against drug pricing legislation in anticipation of an upcoming measure, that would resemble legislation that passed in the House of Representatives in 2019, H.R. 3, the Lower Drug Costs Now Act of 2019.

On March 24, Biocom and the California Life Sciences Association (CLSA) issued a press release unveiling data analyzing the impact of importing foreign price controls on California’s innovation ecosystem, as proposed in H.R. 3. The study was conducted by Vital Transformation, an international health economics firm and commissioned by the Council of State Bioscience Associations, Biocom California and CLSA. Click here to view the release.

Biocom has been strategically communicating the results to the California delegation and relevant committees, emphasizing the devastating 56 percent reduction in industry revenue and 90% reduction in the number of drugs produced by small companies, should H.R. 3 had been in effect over the past 10 years. Biocom also hosted a congressional briefing with state partners across the country.

On the communication side, Biocom is encouraging individuals to write to their Representatives and Senators in opposition to price setting legislation, through our action center. Click here to view our action alert. Biocom also partnered with BIO and CLSA on advertisement placements in California newspapers.